TY - JOUR
T1 - Useful applications of growth factors for cardiovascular regenerative medicine
AU - De Pascale, Maria Rosaria
AU - Della Mura, Nunzia
AU - Vacca, Michele
AU - Napoli, Claudio
N1 - Funding Information:
NDM is funded by an IRCCS SDN clinical research fellowship. CN is funded by a Ricerca Corrente 2018 (Ministero della Salute [Italian Ministery of Health], Rome, Italy].
Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/1
Y1 - 2020/1
N2 - Novel advances for cardiovascular diseases (CVDs) include regenerative approaches for fibrosis, hypertrophy, and neoangiogenesis. Studies indicate that growth factor (GF) signaling could promote heart repair since most of the evidence is derived from preclinical models. Observational studies have evaluated GF serum/plasma levels as feasible biomarkers for risk stratification of CVDs. Noteworthy, two clinical interventional published studies showed that the administration of growth factors (GFs) induced beneficial effect on left ventricular ejection fraction (LVEF), myocardial perfusion, end-systolic volume index (ESVI). To date, large scale ongoing studies are in Phase I-II and mostly focussed on intramyocardial (IM), intracoronary (IC) or intravenous (IV) administration of vascular endothelial growth factor (VEGF) and fibroblast growth factor-23 (FGF-23) which result in the most investigated GFs in the last 10 years. Future data of ongoing randomized controlled studies will be crucial in understanding whether GF-based protocols could be in a concrete way effective in the clinical setting.
AB - Novel advances for cardiovascular diseases (CVDs) include regenerative approaches for fibrosis, hypertrophy, and neoangiogenesis. Studies indicate that growth factor (GF) signaling could promote heart repair since most of the evidence is derived from preclinical models. Observational studies have evaluated GF serum/plasma levels as feasible biomarkers for risk stratification of CVDs. Noteworthy, two clinical interventional published studies showed that the administration of growth factors (GFs) induced beneficial effect on left ventricular ejection fraction (LVEF), myocardial perfusion, end-systolic volume index (ESVI). To date, large scale ongoing studies are in Phase I-II and mostly focussed on intramyocardial (IM), intracoronary (IC) or intravenous (IV) administration of vascular endothelial growth factor (VEGF) and fibroblast growth factor-23 (FGF-23) which result in the most investigated GFs in the last 10 years. Future data of ongoing randomized controlled studies will be crucial in understanding whether GF-based protocols could be in a concrete way effective in the clinical setting.
KW - cardiovascular diseases
KW - fibroblast growth factor
KW - Growth factors
KW - heart failure
KW - vascular endothelial growth factors
UR - http://www.scopus.com/inward/record.url?scp=85092373570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092373570&partnerID=8YFLogxK
U2 - 10.1080/08977194.2020.1825410
DO - 10.1080/08977194.2020.1825410
M3 - Review article
C2 - 33028111
AN - SCOPUS:85092373570
VL - 38
SP - 35
EP - 63
JO - Growth Factors
JF - Growth Factors
SN - 0897-7194
IS - 1
ER -